Sandra E. Reznik, M.D., Ph.D.

• Mentored Clinical Scientist Development Award (NIH K08), 1998–2004

• New York Obstetrical Society Research Fellow Award (Mentor), 2003
   

• St. John’s University Faculty Recognition Awards for Research, 2010–11; 2011–12; 2012 –13; 2013–14; 2014–15; 2015–16; 2016–17; 2017–18; 2018–19; 2019–20; 2020–21
   

• Lumara Health Research Grant Award, 2015
   

• Preterm Birth International Collaborative, Invited Member, 2018–present

1. American Society of Reproductive Immunology, 34th Congress. Scientific Committee to Select Speakers (2014).

2.  Preterm Birth International Collaborative. Facilitator (2021).

3. Preterm Birth International Collaborative. Translational Research and Commercialization Working Group Leader (2022).

4. Preterm Birth International Collaborative, North American Branch. Steering Committee Member

5. Preterm Birth International Collaborative, North American Branch. Translational Research and Commercialization Working Group Leader (2023)

6. PREBIC Initiative on Drug and Diagnostic Development (PID3), Member 

7. Preterm Birth International Collaborative, North American Branch Director 

1. NIH Pregnancy and Neonatology Study Section, Ad Hoc Member, 2008, 2009, 2016 

2. Advancing Therapeutics Study Section, Ad Hoc Member, 2023, 2024

3. Immune Mechanisms at the Maternal-Fetal Interface Study Section, Ad Hoc Member, 2023

• Editorial Board Member, Scientific Reports

• Associate Editor, Frontiers in Neuroscience, Frontiers in Neurology and Frontiers in Psychiatry, Neurodegeneration Section

• Section Editor, Placenta and Reproductive Medicine, Translational Research Section 

Internal Funding

1. MMC-AECOM Department of Pathology Grant
   Title: A Common Pathway to Increased Risk of Perinatal Morbidity and Mortality: The Association of Endothelin-Converting Enzyme, Enkephalinase and Endothelin-1 with Compromise of Uteroplacental Circulation and Pre-Term Labor
   Dates: January 1, 1997–December 31, 1997
   Total Costs: $1,689
   Role: Principal Investigator
    
2. St. John’s University Seed Grant
   Title: Differential Gene Expression in Infection-Associated Preterm Labor: Generation of a Human Gene Expression Bank from a Murine Model, Phase I
   Dates: June 1, 2005–November 30, 2005
   Total Costs: $5,000
   Role: Principal Investigator
    
3. St. John’s University Support of Summer Research Grant
   Title: Differential Gene Expression in Preterm Labor
   Dates: May 10, 2006–August 28, 2006
   Total Costs: $7,000
   Role: Principal Investigator
    
4. St. John’s University Seed Grant
   Title: Differential Gene Expression in Infection-Associated Preterm Labor Generation of a Human Gene Expression Bank from a Murine Model, Phase II
   Dates: June 1, 2007–May 31, 2008
   Total Costs: $5,000
   Role: Principal Investigator 
    
5. St. John’s University Seed Grant
   Title: Effect of Novel Endothelin Receptor Antagonists on Murine Models of Preterm Birth and Cerebral Malaria
   Dates: June 1, 2009–May 31, 2010
   Total Costs: $5,000
   Role: Principal Investigator
    
6. St. John’s University Seed Grant
   Title: Pregnancy Associated Plasma Protein A2: A Novel Biomarker for Trisomy 21
   Dates: June 1, 2010–May 31, 2011
   Total Costs: $5,000
   Role: Principal Investigator
    
7. St. John’s University Seed Grant
   Title: N, N-Dimethylacetamide Suppresses Inflammation by Producing Epigenetic Changes
   Dates: June 1, 2013–May 31, 2014
   Total Costs: $5,000
   Role: Principal Investigator
    
8. St. John’s University Seed Grant
   Title: Defining the Role of Endothelin-1 in Infection-Associated Preterm Birth, Using a Human Placental Ex Vivo Model
   Dates: June 1, 2014–May 31, 2015
   Total Costs: $5,000
   Role: Principal Investigator
    
9. St. John’s University Seed Grant
   Title: The Effect of N,N-Dimethylacetamide on Nuclear Factor Kappa B 
   Dates: June 1, 2015–May 31, 2016
   Total Costs: $5,000
   Role: Principal Investigator
    
10. St. John’s University Seed Grant
    Title: N, N-Dimethylacetamide Prevents Infection-Associated Preterm Birth
    Dates: June 1, 2012–May 31, 2013
    Total Costs: $5,000
    Role: Principal Investigator
     
11. St. John’s University Seed Grant
    Title: N,N-Diethylacetamide and N,N-Dipropylacetamide for Inflammatory Bowel Disease
    Dates: June 1, 2018–May 31, 2019
    Total Costs: $2,500
    Role: Principal Investigator
     
12. Einstein-Mount Sinai Diabetes Research Center Immuno-Technology Core Microgrant
    Title: Developing a Placental Molecular Signature for Increased Risk for Fetal Metabolic Disease
    Dates: April 1, 2021–March 31, 2022
    Total Costs: $10,000
    Role: Principal Investigator (Multi-PI)
     
13. MMC-AECOM Department of Pathology Grant
    Title: Developing Placental Molecular and Cellular Signatures for Increased Risk of Adverse Obstetrical Outcome
    Dates: April 1, 2021–March 31, 2022
    Total Costs: $10,000
    Role: Principal Investigator
     
14. AECOM Diabetes Research Center Catalytic Seed Grant
    Title: Neonatal Intestinal Microbiome Signatures to Predict Childhood Metabolic Dysfunction
    Dates: June 1, 2021–May 30, 2022
    Total Costs: $13,000
    Role: Principal Investigator (Multi-PI)
     
15. MMC-AECOM Department of Pathology Grant
    Title: N,N-Dimethylacetamide and Paclitaxel Combination Therapy to Ameliorate Metastatic Breast Carcinoma in a Preclinical Model
    Dates: June 1, 2025–May 30, 2026
    Total Costs: $9,026
    Role: Principal Investigator (Multi-PI) 

External Funding

1. NIH Grant: 5K08 HD 01209
   Title: Peptide Processing Enzymes in the Placenta
   Dates: April 1, 1998–April 30, 2002; October 1, 2003–February 28, 2005
   Total Costs: $425,790
   Role: Principal Investigator 
    
2. NIH Grant: 1R01NS069577
    Title: Cerebral Malaria: Mechanisms of Disease and Neurological Salvage
    Dates: April 15, 2011–April 14, 2016
    Total Costs: (Sub-award) $297,000
    Role: Co-Investigator
    
3. Lumara Health (AMAG) Research Grant Award
    Title: Investigation of the Anti-Inflammatory and Potential Tocolytic Activities of N,N-Dimethylacetamide-Related Compounds Using In Vitro and Ex Vivo Models
   Dates: December 1, 2015–November 30, 2016
   Total Costs: $25,000
   Role: Principal Investigator
    
4. Nassau Health Care Corporation Contract
   Title: Novel Approaches to Trauma-Induced Pro-inflammatory Responses
   Dates: October 16, 2016–October 15, 2025
   Total Costs: $165,000
   Role: Principal Investigator
    
5. Vifor Pharma Grant
   Title: OM-85 for the Reversal of High Fat Diet Induced Gut Dysbiosis
   Dates: July 17, 2018–July 31, 2021
   Total Costs: $172,300
   Role: Principal Investigator
    
6. Ines Mandl Research Foundation Grant
   Title: Prevention of Inflammation Driven Cervix Remodeling and Preterm Birth
   Dates: February 1, 2020–December 2022
   Total Costs: $60,000
   Role: Principal Investigator
    
7. NIH Grant: 1R16GM145586 (including supplement)
   Title: N,N-Dimethylacetamide Vaginal Self-emulsifying Drug Delivery System for the Prevention of Preterm Birth
   Dates: May 11, 2022–April 30, 2026
   Total Costs: $723,125
   Role: Principal Investigator        

Patents

• Reznik SE, Ashby CR and Cantor JO. Administration of N,N-Dimethylacetamide for the Treatment of Preterm Birth. Patent No. 11,717,499B2.

Invited Lectures

1. The Role of Endothelin-1 in Preterm Labor and Its Inhibition by Novel 1,3,6-Trisubstituted 4 Quinolone ETA Receptor Antagonists. American Chemical Society Address (2008).
    
2. From Mice to Microarrays: Identifying the Key Players in Infection-Associated Preterm Birth.   Department of Applied Sciences, Winthrop University Hospital, Mineola, NY Seminar (2010).
    
3. The Mechanism of Action of Plan B. Press Conference, Columbus, OH (2010).
    
4. The Mechanism of Action of Plan B. Brown Bag Presentation to Ohio Legislature (2010).
    
5. The Mechanisms of Action of Mifepristone, Ulipristal and Levonorgestrel. NARAL Pro-Choice New York / National Institute for Reproductive Health Teleconference (2010).
    
6. Dimethylacetamide Controls Infection-Associated Preterm Birth in a Murine Model: An Accidental Discovery. Department of Applied Sciences, Winthrop University Hospital Research Institute, Mineola, NY Seminar (2011).
    
7. Novel Approaches to Inflammation-Associated Preterm Birth. Department of Pediatrics, Feinstein Institute for Medical Research, Manhasset, NY Seminar (2015).
    
8. The Organ That Determines Our Future: Environmental Effects on the Placenta. CDC/NIOSH Seminar (2017).
    
9. An Accidental Discovery: N,N-Dimethylacetamide and Its Analogs for the Prevention of Inflammation Driven Preterm Birth. Society for Reproductive Investigation’s Joint Preterm Birth International Collaborative and Myometrium/Parturition Satellite Symposium Lecture (2018).
    
10. The Treasure Under Our Noses: N,N-Dimethylacetamide and Its Analogs for the Prevention of Preterm Birth. Preterm Birth International Collaborative North American Branch Inaugural Meeting Lecture (2018).
     
11. A Solution Under Our Noses: "DMA" and Its Analogs are Novel Anti-inflammatory Compounds. Nassau University Medical Center Emergency Department Grand Rounds (2020).
     
12. The Role of Placental Pathology in Birth Injury Cases. Presented to Morgan & Morgan Law Firm (2021).
     
13. Seeking Approval for Preterm Birth Drug Therapy: Can We Overcome the Challenges? Preterm Birth International Collaborative North American Branch Talk (2022).
     
14. The Role of Placental Pathology in Birth Injury Cases. Mastering the Medicine: Medical Negligence and Birth Trauma Seminar. American Association for Justice Education (2022).
     
15. Novel Approaches to Preterm Birth Prevention. Sixth Longo Symposium, Lawrence D. Longo, MD Center for Perinatal Biology, Loma Linda University School of Medicine (2024).
16. Novel Approaches to Preventing Preterm Birth. Preterm Birth International Collaborative (PREBIC) Young Investigator Forum Talk (2024).
     
17. Unlocking the Untapped Therapeutic Potential of the FDA-Approved Drug Excipient N,N-Dimethylacetamide. Nassau University Medical Center Emergency Department Grand Rounds (2025).
     
18. Preterm Birth from a North America Context. Preterm Birth International Collaborative Global Meeting Talk (2025).
     
19. From Inert Excipient to Targeted Therapy: Vaginal Delivery of N,N-Dimethylacetamide via Nanoemulsifying Delivery System for Inflammation-Driven Preterm Birth. Society for Reproductive Investigation Talk (2026).

Bibliography

Experimental Papers

1. Lasdun A, Reznik S, Molineaux, CJ and Orlowski M. Inhibition of Endopeptidase 24.15 Slows the in Vivo Degradation of Luteinizing Hormone-Releasing Hormone. J Pharm Exp Ther 251: 439-447 (1989).
    
2. Orlowski M, Reznik S, Ayala J and Pierotti AR. Endopeptidase 24.15 From Rat Testes.  Isolation of the Enzyme and Its Specificity Toward Synthetic and Natural Peptides, Including Enkephalin-Containing Peptides. Biochem J 261: 951-958 (1989).
    
3. Reznik S. Endopeptidase 24.15, A Neuropeptide Metabolizing Enzyme: Isolation, Localization, Possible Function. Ph.D. Dissertation (1990).
    
4. Reznik S, Salafia CM, Lage J and Fricker LD. The Distribution of Carboxypeptidases E and D in the Placenta and Umbilical Cord. J Histochem Cytochem 46: 1359-1367 (1998).
    
5. Novikova E, Reznik S, Varlamov O and Fricker LD. Carboxypeptidase Z is Present in the Regulated Secretory Pathway and Extracellular Matrix in Cultured Cells and in Human Tissues. J Biol Chem 275: 4865-5870 (2000).
    
6. Ahmad Z and Reznik SE. Immunohistochemical Localization of ECE-1 in the Human Placenta. Placenta 21: 226-233 (2000).
    
7. Novikova E, Fricker LD and Reznik SE. Metallocarboxypeptidase Z is Dynamically Expressed in Mouse Development. Mech Dev 202: 259-262 (2001).
    
8. Feng Y, Reznik SE and Fricker LD. The Distribution of Pro-SAAS-Derived Peptides in Rat Neuroendocrine Tissues. Neuroscience 105: 469-478 (2001).
    
9. Feng Y, Reznik SE and Fricker LD. ProSAAS-Derived Peptides and Prohormone Convertase 1 are broadly Expressed During Mouse Development. Gene Express Patterns 1: 135-140 (2002).
    
10. Koscica K, Sylvestre G and Reznik SE. The Effect of Phosphoramidon on Inflammation-Mediated Preterm Delivery in a Mouse Model. Am J Obstet Gynecol 190: 528-531 (2004).
     
11. Koscica K, Ananth CV, Placido J and Reznik SE. The Effect of a Matrix Metalloproteinase Inhibitor on Inflammation-Mediated Preterm Delivery. Am J Obstet Gynecol 196: 551.e1-551.e3 (2007).
     
12. Bhavsar TM, Cerreta JM, Liu M, Reznik SE and Cantor JO. Phosphoramidon, an Endothelin-Converting Enzyme Inhibitor, Attenuates Lipopolysaccharide-Induced Acute Lung Injury. Exper Lung Res 34: 141-154 (2008).
     
13. Vu T-D, Feng Y, Placido J and Reznik SE. Placental Matrix Metalloproteinase-1 Is Up-Regulated in Labor. Reprod Sci 15: 420-424 (2008). 
     
14. Klugman SD, Gross SJ, Khabele D, Liang J, Livne K, Lopez-Jones M, Gross B, Cordero D and Reznik SE. Expression of Keratin 8 and TRAIL in Down Syndrome Placentas. Placenta 29: 382-384 (2008).
     
15. Olgun N, Patel H, Wang W, Yen H, Stephani R and Reznik SE. Effect of the Putative, Novel Selective ETA Receptor Antagonist HJP272, a 1,3,6-Trisubstituted-2-carboxy-quinol-4-one, on Infection Mediated Premature Delivery. Can J Physiol Pharmacol 86: 571-575 (2008).
     
16. Wang W, Yen H, Chen C-H, Soni R, Jasani N, Sylvestre G and Reznik SE. The Endothelin Converting Enzyme-1 (ECE-1)/Endothelin-1 (ET-1) Pathway Plays a Critical Role in Infection-Associated Premature Delivery in a Mouse Model. Am J Path 173: 1077-1084 (2008).
     
17. Wang W, Yen H, Chen C-H, Jasani N, Soni R, Koscica K and Reznik SE. Endothelin-1 and Matrix Metalloproteinase-1 Function in the Same Molecular Pathway in Infection-Associated Preterm Birth. Molec Med 16: 505-512 (2010).
     
18. Olgun NS, Stephani RA, Patel HJ and Reznik SE. Blockade of Endothelin-1 With a Novel Series of 1,3,6-Trisubstituted-2-carboxy-quinol-4-one’s Controls Infection-Associated Preterm Birth. Am J Path 177: 1929-1935 (2010).
     
19. Dai M, Reznik SE, Spray DC, Weiss LM, Tanowitz HB, Gulinello M and Desruisseaux MS. Persistent Cognitive and Motor Deficits After Successful Antimalarial Treatment in Murine Cerebral Malaria. Microbes Infect 12: 1198-1207 (2010).
     
20. Patel HJ, Olgun NS, Lengyel I, Reznik SE and Stephani RA. Synthesis and Pharmacological Activity of 1,3,6-Trisubstituted-4-Oxo-1,4-Dihydroquinoline-2-Carboxylic Acids as Selective ETA Antagonists. Bioorg Med Chem Lett 20: 6840-6844 (2010).
     
21. Ouhilal S, Vuguin P, Cui L, Du X-Q, Gelling RW, Reznik SE, Russell R, Parlow AF, Karpovsky C, SantoroN and Charron MJ. Hypoglycemia, Hyperglucagonemia and Feto-placental Defects in Glucagon Receptor Knockout Mice: A Role for Glucagon Action in Pregnancy Maintenance. Am J Phys Endo Metab 302: E522-E531 (2012).
     
22. Dai M, Freeman B, Shikani HJ, Bruno FP, Weiss LM, Tanowitz HB, Spray DC, Macias R, Reznik SE, and Desruisseaux MS.  Altered Regulation of Akt Signaling with Murine Cerebral Malaria, Effects on Long-term Neuro-cognitive Function, Restoration with Lithium Treatment. PLoS One 7: e44117 (2012).
     
23. Dai M, Shikani HJ, Freeman B, Bruno FP, Tanowitz HB, Weiss LM, Reznik SE, Stephani RA, and Desruisseaux MS. A Novel Endothelin Receptor Antagonist Prevents Cerebral Microvascular Hemorrhage When Used in Conjunction with an Anti-malarial Agent in Plasmodium berghei ANKA-infected Mice. Life Sci 91: 687-692 (2012).
     
24. Sundaram S, Ashby CR, Pekson R, Sampat V, Sitapara R, Mantell L, Chen C-H, Yen H, Abhichandani K, Munnangi S, Khadtare N, Stephani RA and Reznik SE. N,N-Dimethylacetamide Regulates the Pro-inflammatory Response Associated with Endotoxin and Prevents Preterm Birth. Am J Path 183: 422-430 (2013).
     
25. Lulla A, Reznik SE, Trombetta L and Billack B. Use of the Mouse Ear Vesicant Model to Evaluate the Effectiveness of Ebselen as a Countermeasure to the Nitrogen Mustard Mechlorethamine. J App Tox 34: 1373-1378 (2014).
     
26. Munnangi S, Gross SJ, Madankumar R and Reznik SE. Pregnancy Associated Plasma Protein-A2: A Novel Biomarker for Down Syndrome. Placenta 35: 900-906 (2014).
     
27. Adler E, Madankumar R, Rosner M and Reznik SE. Increased Placental Trophoblast Inclusions in Placenta Accreta. Placenta 35: 7035-7038 (2014).
     
28. Olgun NS, Hanna N and Reznik SE. BQ-123 Prevents LPS-Induced Preterm Birth Via the Induction of Uterine and Placental IL-10. Tox App Pharm 282: 275-284 (2015).
     
29. Vyas V, Ashby CR, Olgun NS, Sundaram S, Salami O, Munnangi S, Pekson R, Mahajan P and Reznik SE. Inhibition of Sphingosine Kinase Prevents Lipopolysaccharide Induced Preterm Birth and Suppresses Pro-inflammatory Responses in a Murine Model. Am J Path 185: 862-869 (2015).
     
30. Suzuki M, Maekawa R, Patterson ME, Reynolds DM, Calder BR, Reznik SE, Heo HJ, Einstein FH and Greally JM. Amnion as a Surrogate Tissue Reporter of the Effects of Preeclampsia on the Fetus. Clin Epigen 8: 67 (2016).
     
31. Pekson R, Poltoratsky V, Gorasiya S, Sundaram S, Ashby CR, Vancurova I and Reznik SE. N,N-Dimethylacetamide Significantly Attenuates LPS- and TNFα-Induced Proinflammatory Responses Via Inhibition of the Nuclear Factor Kappa B Pathway. Molec Med 22: 747-758 (2016).
     
32. Manuel CR, Charron M, Ashby CR and Reznik SE. Saturated and Unsaturated Fatty Acids Differentially Regulate In Vitro and Ex Vivo Placental Antioxidant Capacity. Am J Reprod Immunol 80: e12868 (2018) https://doi.org/10.1111/aji.12868. (Featured on journal cover.)
     
33. Reidy KJ, Hjorten RC, Simpson CL, Rosenberg AZ, Rosenblum SD, Kovesdy CP, Tylavsky FA, Myrie J, Ruiz BL, Mozhui K, Haque S, Suzuki M, Jacob J, Reznik SE, Kaskel FJ, Kopp JB, Winkler CA and Davis RL. Fetal Not Maternal apol1 Genotype Associated with Risk for Preeclampsia. Am J Hum Gen 103: 367-376 (2018).
     
34. De Vera AA, Gupta P, Lei Z, Liao D, Narayanan S, Teng Q, Chen Z-S and Reznik SE. Immuno-oncology Agent IPI-549 Is a Modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-Mediated Multi-drug Resistance (MDR) in Cancer: In Vitro and In vivo. Cancer Lett 442: 91-103 (2019).
     
35. Manuel CR, Latuga MS, Ashby CR and Reznik SE. Immune Tolerance Attenuates Gut Dysbiosis, Dysregulated Uterine Gene Expression and High-Fat Diet Potentiated Preterm Birth in Mice. Am J Obstet Gynecol, 220: 596.e1-596.e28 (2019).
     
36. Patki M, Giusto K, Gorasiya S, Patel K* and Reznik SE*. 17--Hydroxyprogesterone Nanoemulsifying Preconcentrate Loaded Vaginal Tablet: A Novel Non-invasive Approach for the Prevention of Preterm Birth. Pharmaceutics 11: 335 (2019). *Equal contributors.
     
37. Williams L, Burgos E, Vuguin P, Manuel C, Pekson R, Munnangi S, Charron M* and Reznik SE*. N-Acetylcysteine Resolves Placental Inflammatory-Vasculopathic Changes in Mice Consuming a High Fat Diet. Am J Path 189: 2246-2257 (2019). *Equal contributors.
     
38. Gandhi T, Patki M, Kong J, Koya J, Yoganathan S, Reznik SE and Patel K. Development of Arginine Anchored Nano-globule with Retrograde Trafficking Inhibitor (Retro-2) for the Treatment of Enterohemorrhagic Escherichia Coli Outbreak. Mol Pharm 16: 4405-4415 (2019).
     
39. Giusto K, Patki M, Koya J, Ashby CR, Munnangi S, Patel K* and Reznik SE*. A Vaginal Nanoformulation of a Sphingosine Kinase Inhibitor Attenuates LPS-induced Preterm Birth in Mice. Nanomedicine (Lond.) 14: 2835-2851 (2019). *Co-corresponding authors.
     
40. Gupta P, Ashar YV, Teng Q-X, Lei Z, Chen B, Reznik SE, Wurpel JND and Chen Z-S. KIT and PDGFRA Inhibitor Avapritinib (BLU-285) Overcomes ABCB1- and ABCBG2-mediated MDR in Cancer Cells. J Molec Clin Med 2: 69-78 (2019).
     
41. Olgun SN, Morris AM, Bowers LN, Stefaniak LB, Friend SA, Kashon ML, Reznik SE and Leonard SS. Mild Steel and Stainless Steel Welding Fumes Elicit Pro-Inflammatory and Pro-Oxidant Effects in First Trimester Trophoblast Cells, Am J Reprod Immunol: 0:313221 (2020).
     
42. Charron MJ, Williams L, Seki Y, Du XQ, Chaurasia B, Saghatelian A, Summers SA, Katz EB, Vuguin PM and Reznik SE. Antioxidant Effects of N-Acetylcysteine Prevent Programmed Metabolic Disease in Mice. Diabetes 69: 1650-1661 (2020).
     
43. Ashar YV, Zhou J, Gupta P, Teng Q-X, Lei Z-N, Reznik SE, Lusvarghi S, Wurpel JND, Ambudkar SV and Chen Z-S. BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Reverses ABCG2-mediated Multidrug Resistance. Cancers 12: 2502 (2020).
     
44. Patki M, Palekar S, Reznik SE and Patel K. Self-injectable Extended Release Formulation of Remdesivir (SelfExRem): A Potential Formulation Alternative for COVID-19 Treatment. Int J Pharm 597: 120329 (2021).
     
45. Fu Y, Saraswat A, Agrawal MY, Wei Z, Dukhande VV, Reznik SE and Patel K. Development of Dual ARV-825 and Nintedanib-Loaded Pegylated Nano-Liposomes for Synergistic Efficacy in Vemurafenib-resistant Melanoma. Pharmaceutics 13: 1005 (2021).
     
46. Wei Z, Salami OO, Koya J, Munnangi S, Pekson R, Ashby CR and Reznik SE. N,N-Dimethylformamide Delays LPS-Induced Preterm Birth in a Murine Model by Suppressing the Inflammatory Response. Reprod Sci 29: 2894-2907 (2022).
     
47. Koya J, Shen T, Lu G, Gauthier A, Mantell L, Ashby CR and Reznik SE. FDA-Approved Excipient N,N-Dimethylacetamide Attenuates In Vitro and In Vivo Inflammatory Bowel Disease. Fortune J Health Sci 5: 499-509 (2022).
     
48. Fagiola M, Reznik SE, Raiz M, Qyang Y, Lee S, Avella J, Turino G and Cantor JO. The Relationship Between Elastin Crosslinking and Alveolar Wall Rupture in Human Pulmonary Emphysema. Am J Phys Lung Cell Mol Physiol 324: L747-L755 (2023).
     
49. Wei Z, Koya J, Acharekar N, Trejos J, Dong X-D, Schanne FA, Ashby CR and Reznik SE. N-N-Dimethylacetamide Attenuates Neuroinflammation in Alzheimer’s Disease in In-vitro and Ex-vivo Models. Sci Rep 13: 7077 (2023).
     
50. Reznik SE, Vuguin PM, Cohen A, Khoury R, Loudig O, Balakrishnan R, Fineberg SA, Hughes F, Harigopal M, Charron MJ. SARS-CoV-2 Infection in Unvaccinated High-risk Pregnant Women in the Bronx, NY, USA is Associated with Decreased Apgar Scores and Placental Villous Infarcts. Biomolecules 13: 1224 (2023).
     
51. Akinyemi AJ, Du XQ, Aguilan J, Sidoli S, Hirsch D, Wang T, Reznik SE, Fuloria M, Charron MJ. Human Cord Plasma Proteomic Analysis Reveals Sexually Dimorphic Proteins Associated with Intrauterine Growth Restriction. Proteomics e2300260 (2023).
     
52. Reznik SE, Akinyemi AJ, Harary D, Latuga MS, Fuloria M, Charron MJ. The Effect of Cesarean Delivery and the Neonatal Gut Microbiome in an Under-resourced Population in the Bronx, NY, USA. BMC Pediatrics 24: 450 (2024).
     
53. Hewady S, Manuel CR, Pasquali C, Koya J, Reznik SE. OM-85 Attenuates High-Fat Diet-Induced Obesity, Insulin Resistance, Gut Dysbiosis and Nonalcoholic Steatohepatitis in a Murine Model. Biomed Pharmacother 181: 117710 (2024).
     
54. Islam MA, Khairnar R, Fleishman J, Reznik SE, Ragolia L, Gobbooru S, Kumar S. Female C57BL/6 Mice Exhibit Protection Against Nonalcoholic Fatty Liver Disease and Diabesity Accompanied by Differential Regulation of Hepatic Lipocalin Prostaglandin D2 Synthase. Molec Cell Endo 595: 112404 (2025).
     
55. Reznik SE, Kashou A, Ward D and Yellon SM. N,N-Dimethylacetamide Blocks Inflammation-Induced Preterm Birth and Remediates Maternal Systemic Immune Responses. Sci Rep 15: 8234 (2025).
     
56. Mir A, Acosta T, Concheiro-Guisan M, Yellon SM, Patel K and Reznik SE. Improving the Safety of N,N-Dimethylacetamide (DMA) as a Potential Treatment for Preterm Birth in a Pregnant Mouse Model Using a Vaginal Nanoformulation. BBA – Molec Basis Dis 1871: 167822 (2025).
     
57. Baig N, Chilamakuri R, Agarwal S, Muth A and Reznik SE. HJP 272, an Endothelin Receptor Antagonist, and Its Role in Cancer Cell Migration and Invasion. Trans Oncol, 60: 102492 (2025).
     
58. Gorasiya S, Mushi J, Yoganathan S, Barasa L, Pekson R, Ashby CR and Reznik SE. N,N-Diethylacetamide and N,N-Dipropylacetamide Inhibit the NF-kB Pathway in In Vitro, Ex Vivo and In Vivo Models of Inflammation-Induced Preterm Birth. Sci Rep 15: 29861 (2025).

Review Articles, Book Chapters, and Contributions to Textbooks

1. Reznik SE and Fricker LD. Carboxypeptidases from A to Z: Implications in Embryonic Development and Wnt Binding. Cell Mol Life Sci 58: 1790-1804 (2001).
    
2. Reznik SE. Sample Expert Witness Report in: The Medical Record As Evidence, EB Oppenheim, Lexis Law Pub. Co., Charlottesville, VA, Supplement: 175-178 (2003).
    
3. Reznik SE. “Plan B:” How It Works. Science Shows It Is Not An Abortifacient. Health Prog 91: 59-61 (2010).
    
4. Olgun NS and Reznik SE. The Matrix Metalloproteases and Endothelin-1 in Preterm Birth. Obstet Gynecol Internat 2010: 657039 (2010).
    
5. Vyas V, Ashby CR and Reznik SE. Sphingosine Kinase: A Novel Putative Target for the Prevention of Infection-Triggered Preterm Birth. Obstet Gynecol Internat 2013:302592 (2013).
    
6. Sahasrabudhe N, Mobasseri M, Reznik SE and Williams Z. Chronic Endometritis and Recurrent Pregnancy Loss. Curr Obstet Gynecol Rep 6: 55-61 (2017).
    
7. Manuel CR, Ashby CR and Reznik SE. Discrepancies in Animal Models of Preterm Birth, Curr Pharm Des 23: 6142-6148 (2017).
    
8. Gorasiya S, Mushi J, Giusto K, Pekson R, Yoganathan S and Reznik SE. Repurposing N,N-Dimethylacetamide (DMA), a Pharmaceutical Excipient, as a Prototype Novel Anti-inflammatory Agent for the Prevention and/or Treatment of Preterm Birth. Curr Pharm Des 24: 989-992 (2018).
    
9. De Vera AA and Reznik SE. Combining PI3K/Akt/mTOR Inhibition with Chemotherapy. In Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, part of the series: Cancer Sensitizing Agents for Chemotherapy (2018).
    
10. Teng Q-X, Ashar YV, Gupta P, Gadee E, Fan Y-F, Reznik SE, Wurpel JND and Chen Z-S. Revisiting mTOR Inhibitors as Anti-Cancer Agents. Drug Disc Today 24: 2086-2095 (2019).
     
11. Bo L, Zhang Y-K, Reznik SE* and Chen Z-S*. Eganelisib (IPI-549): First-in-Class Immuno-oncology Candidate in Triple-Negative Breast Cancer (TNBC). Drugs Future 46: 963-975 (2021). *Co-corresponding authors.
     
12. Wei Z, Koya J and Reznik SE. Insulin Resistance Exacerbates Alzheimer Disease Via Multiple Mechanisms. Front Neurosci 15: 884 (2021).
     
13. Wei Z, Koya J, Dong X, Reznik SE* and Chen Z-S*. Spleen Tyrosine Kinase (STK) Inhibitor: Hematological Cancer Therapy. Drugs Future 47: 99-107 (2022). *Co-corresponding authors.
     
14. Mir A, Patel K, Yellon SM and Reznik SE. Vaginal Nanoformulations for the Management of Preterm Birth. Pharmaceutics 14: 2019 (2022).
     
15. Williams S, Rosenblatt KP, Reznik SE, Misra D, Siricilla S, Taylor BD, Gomez-Lopez N, Adams Waldorf KM, Menon R. and PREBIC North America 2024. Defining Knowledge Gaps in Preterm Birth Research: Can Biomarkers Fill the Gaps? Front Med 12: 1655833 (2025).

Case Reports

1. Saksenberg V, Bauch B and Reznik SE. Massive Acute Thymic Hemorrhage and Cerebral Hemorrhage in an Intrauterine Fetal Death. J Clin Path 54: 796-797 (2001).
    
2. Shanske AL, Pande S, Arel K, Vega-Rich C, Brion L, Reznik S and Timor-Tritsch LE. Omphalocele-Exstrophy-Imperforate Anus-Spinal Defects (OEIS) in Triplet Pregnancy After IVF and CVS. Birth Defects Research (Part A) 67: 467-471 (2003).
    
3. Patel M, Beckerman KP, Reznik S, Madan RP and Goldman D. Vertical Transmission of Cryptococcus neoformans to an HIV-exposed Premature Neonate, J Perinatol 32: 235-237 (2012).
    
4. Kuan K and Reznik SE. Intrauterine Fetal Demise and Intestinal Atresia: An Autopsy Investigation. Acad Pathol 7: DOI: 10.1177/2374289520909498 (2020).
    
5. Estrada F, Mahant A, Guerguis S, Sy S, Lu C, Reznik S and Herold B. Preterm Rupture of Membranes Associated with Disseminated Herpes Simplex Virus Type 1 at Birth: Is There a Role for Preemptive Test and Treat Strategies in High-Risk Populations? J Pediatr Infect Dis 12:246-247 (2023).

Letters and Editorials

1. Reznik S. Skinny Lips. Mod Pathol 7: 714-715 (1994).Reznik SE. Letter to the Editor Responding to Commentary Criticizing Health Progress Article. Ethics and Medics (2010).
    
2. Reznik SE, Gardner E and Ashby CR. Cannabidiol: A Potential Treatment for Post Ebola Syndrome? Int J Inf Dis 52: 74-76 (2016).
    
3. Reznik SE and Ashby CR. Sofosbuvir: An Anti-Viral Drug with Potential Efficacy Against Zika Infection. Int J Inf Dis 55: 29-30 (2017).
    
4. Reznik SE. Editorial: Novel Pharmacotherapeutic Targets and Emerging Approaches to Preterm Birth, Part 1. Curr Pharm Des 23: 6097 (2017).>
    
5. Reznik SE. Editorial: Novel Pharmacotherapeutic Targets and Emerging Approaches to Preterm Birth Part 2. Curr Pharm Des 24: 959 (2018).
    
6. Reznik SE, Tiwari AK and Ashby CR. Sofosbuvir: A Potential Treatment for Ebola. Front Pharm 9: 1139 (2018).
    
7. Reznik SE, Tiwari AK and Ashby CR. Potential Use of Sofosbuvir for the Prophylaxis of Rabies. Front Pharm 11: 472 (2020).
    
8. Ashby CR, Tiwari AK and Reznik SE. Edaravone: A Potential Treatment for the COVID-19-induced Inflammatory Syndrome? Pharmacol Res 160: 105055 (2020).
    
9. Reznik SE, Tiwari AK and Ashby CR. Intravenous Immunoglobulin: A Potential Treatment for the Post-Acute Sequelae of SARS-CoV-2 (PASC)? Biomol Biomed 22:660-664 (2022).
    
10. Reznik SE. New Hope for the Prevention of Preterm Birth: Vaginal Nanoformulations. Placenta Repro Med 1: 107 (2022).
     
11. Reznik SE, Tiwari AK and Ashby CR. Efgartigimod, an FcRn Antagonist, as a Potential Treatment for the Post COVID-19 Syndrome. Acta Materia Medica 2: 255-259 (2023).
     
12. Reznik SE, Tiwari AK, Chavda V and Ashby CR. The Delivery of N-myc Downstream-regulated Gene (NDRG2) Self-amplifying mRNA via Modified Lipid Nanoparticles as a Potential Treatment for Drug-resistant and Metastatic Cancer. Med Rev, 4: 235-238 (2024).

Dr. Reznik is a nationally recognized expert in perinatal and placental pathology and frequently called upon to serve as an expert witness in medical malpractice cases.